In vitro ravuconazole susceptibility of anthropophilic dermatophyte strains from Japanese patients.

In vitro ravuconazole susceptibility of anthropophilic dermatophyte strains from Japanese patients. Jpn J Infect Dis. 2019 Dec 25;: Authors: Kano R, Hiruma J, Yokota M, Noguchi H, Hase M, Kamata H, Harada K, Hiruma M Abstract Ravuconazole (RVCZ) is a new available human anti-fungal azole drug in Japan since 2018 and broad spectrum antifungal agent that exhibits excellent activity against dermatophytes. In the present study, the in vitro RVCZ susceptibility of clinical isolates for anthropophilic dermatophytes including the itraconazole (ITCZ) low susceptible and the terbinafin (TEBR) resistance strains of T. interdigitale, was investigated using the Clinical & Laboratory Standards Institute (CLSI) M38-A2 test. The MICs for the 20 clinical isolates of T. interdigitale were <0.03125-0.125 mg/L, 4 clinical isolates of T. rubrum were <0.03125-0.0625 mg/L, and 20 clinical isolates of T. tonsurans were <0.03125 mg/L. Similarly, the MICs for the ITCZ low susceptible and the TEBR resistance strains of T. interdigitale were also <0.03125 mg/L for RVCZ, respectively. To our knowledge, this is first study to investigate the in vitro susceptibility of ITCZ low susceptible and the TEBR resistance strains of T. interdigitale to RVCZ. Our results of this study indicated that RVCZ was most effective to these strains. PMID: 31875604 [PubMed - as supplied by publisher]
Source: Japanese Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Jpn J Infect Dis Source Type: research